Results 201 to 210 of about 45,682,230 (340)

In vitro properties of patient serum predict clinical outcome after high dose rate brachytherapy of hepatocellular carcinoma

open access: yesMolecular Oncology, EarlyView.
Following high dose rate brachytherapy (HDR‐BT) for hepatocellular carcinoma (HCC), patients were classified as responders and nonresponders. Post‐therapy serum induced increased BrdU incorporation and Cyclin E expression of Huh7 and HepG2 cells in nonresponders, but decreased levels in responders.
Lukas Salvermoser   +14 more
wiley   +1 more source

Volumen 12 Número 1 Enero Junio 2020

open access: yesRevista de la Facultad de Ciencias Agropecuarias, 2020
Volumen 12 Número 1 Enero Junio 2020
doaj  

Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine

open access: yesMolecular Oncology, EarlyView.
The CDK9 inhibitor AZD4573 downregulates c‐MYC and MCL‐1 to induce death of cytarabine (AraC)‐resistant AML cells. This enhances VEN + AZA‐induced cell death significantly more than any combination of two of the three drugs in AraC‐resistant AML cells.
Shuangshuang Wu   +18 more
wiley   +1 more source

Early posttransplant rituximab use in kidney transplant recipients with preexisting donor-specific antibodies. [PDF]

open access: yesRen Fail
Yamauchi J   +9 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy